Targeted imaging of hypoxia-induced integrin activation in myocardium early after infarction

Journal of Applied Physiology

Volumn 104, Issue 5, 2008, Pages 1504-1512

  Kalinowski, Leszek ^a,b   Dobrucki, Lawrence W ^a   Meoli, David F ^a   Dione, Donald P ^a   Sadeghi, Mehran M ^a   Madri, Joseph A ^a   Sinusas, Albert J ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Angiogenesis; Myocardial infarction; Radiotracer imaging

Indexed keywords

BRU 59 21; BRU 59 21 TC 99M; INDIUM 111; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; NITROIMIDAZOLE; OXO TRIS[3,3,9,9 TETRAMETHYL 5 OXA 6 (2 NITRO 1H IMIDAZOL 1 YL) 4,8 DIAZAUNDECANE 2,10 DIONE DIOXIMATO] N,N',N'',N''' TC 99M; RP 748; RP 790; TECHNETIUM 99M; THALLIUM 201; TRACER; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; ACTIN; BIOLOGICAL MARKER; BRU 59-21; DIAGNOSTIC AGENT; IMIDAZOLE DERIVATIVE; INTEGRIN; ORGANOMETALLIC COMPOUND; RADIOPHARMACEUTICAL AGENT; SINGLE HETEROCYCLIC RINGS; TECHNETIUM COMPLEX;

ACUTE HEART INFARCTION; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG TARGETING; DRUG UPTAKE; HEART INFARCTION; HYPOXIA; IMAGING SYSTEM; IMMUNOHISTOCHEMISTRY; ISOTOPE LABELING; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SCINTILLATION CAMERA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ANIMAL; ANOXIA; BIOSYNTHESIS; BIOTRANSFORMATION; DOG; GENETICS; HEART MUSCLE; HEART MUSCLE ISCHEMIA; METABOLISM; PATHOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ACTINS; ANIMALS; ANOXIA; BIOLOGICAL MARKERS; BIOTRANSFORMATION; DOGS; HETEROCYCLIC COMPOUNDS, 1-RING; IMIDAZOLES; IMMUNOHISTOCHEMISTRY; INTEGRIN ALPHAVBETA3; INTEGRINS; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; MYOCARDIUM; NEOVASCULARIZATION, PHYSIOLOGIC; ORGANOMETALLIC COMPOUNDS; ORGANOTECHNETIUM COMPOUNDS; RADIOPHARMACEUTICALS; RATS; RATS, SPRAGUE-DAWLEY; TECHNETIUM TC 99M SESTAMIBI; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 45149111674     PISSN: 87507587     EISSN: 15221601     Source Type: Journal    
DOI: 10.1152/japplphysiol.00861.2007     Document Type: Article

References (27)

1. Baklanov D, Simons M. Arteriogenesis: lessons learned from clinical trials. Endothelium 10: 217-223, 2003.
2. Bogdanov AA, Lewin M, Weissleder R. Approaches and agents for imaging the vascular system. Adv Drug Delivery Res 37: 279-293, 1999.
3. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264: 569-571, 1994.
4. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, Cheresh DA. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79: 1157-1164, 1994.
5. Di Rocco RJ, Bauer AA, Pirro JP, Kuczynski BL, Belnavis L, Chan YW, Linder KE, Narra RK, Nowotnik DP, Nunn AD. Delineation of the border zone of ischemic rabbit myocardium by a technetium-labeled nitroimidazole. Nucl Med Biol 24: 201-207, 1997.
6. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364, 1996.
7. Harris TD, Kalogeropoulos S, Nguyen T, Liu S, Bartis J, Ellars C, Edwards S, Onthank D, Silva P, Yalamanchili P, Robinson S, Lazewatsky J, Barrett J, Bozarth J. Design, synthesis, and evaluation of radiolabeled integrin alpha v beta 3 receptor antagonists for tumor imaging and radiotherapy. Cancer Biother Radiopharm 18: 627-641, 2003.
8. Kleiman NS, Patel NC, Allen KB, Simons M, Yla-Herttuala S, Griffin E, Dzau VJ. Evolving revascularization approaches for myocardial ischemia. Am J Cardiol 92: 9N-17N, 2003.
9. Kumar CC. Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis. Curr Drug Targets 4: 123-131, 2003.
10. Lee SH, Wolf PL, Escudero R, Deutsch R, Jamieson SW, Thistlethwaite PA. Early expression of angiogenesis factors in acute myocardial ischemia and infarction. N Engl J Med 342: 626-633, 2000.
11. 99mTc-labeled 2-nitroimidazole for imaging hypoxia in tumors. J Nucl Med 41: 169-176, 2000.
12. Meoli DF, Sadeghi MM, Krassilnikova S, Bourke BN, Giordano FJ, Dione DP, Su H, Edwards DS, Liu S, Harris TD, Madri JA, Zaret BL, Sinusas AJ. Noninvasive imaging of myocardial angiogenesis following experimental myocardial infarction. J Clin Invest 113: 1684-1691, 2004.
13. O'Connor MK, Caiati C, Christian TF, Gibbons RJ. Effects of scatter correction on the measurement of infarct size from SPECT cardiac phantom studies. J Nucl Med 36: 2080-2086, 1995.
14. Ruoslahti E, Engvall E. Integrins and vascular extracellular matrix assembly. J Clin Invest 100: S53-S56, 1997.
15. Sabia PJ, Powers ER, Ragosta M, Sarembock IJ, Burwell LR, Kaul S. An association between collateral blood flow and myocardial viability in patients with recent myocardial infarction. N Engl J Med 327: 1825-1831, 1992.
16. Sadeghi MM, Krassilnikova S, Zhang J, Gharaei AA, Fassaei HR, Esmailzadeh L, Kooshkabadi A, Edwards S, Yalamanchili P, Harris TD, Sinusas AJ, Zaret BL, Bender JR. Detection of injury-induced vascular remodeling by targeting activated alphavbeta3 integrin in vivo. Circulation 110: 84-90, 2004.
17. Senger DR, Ledbetter SR, Claffey KP, Papadopoulos-Sergiou A, Peruzzi CA, Detmar M. Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. Am J Pathol 149: 293-305, 1996.
18. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359: 843-845, 1992.
19. Shyu KG, Wang MT, Wang BW, Chang CC, Leu JG, Kuan P, Chang H. Intramyocardial injection of naked DNA encoding HIF-1alpha/VP16 hybrid to enhance angiogenesis in an acute myocardial infarction model in the rat. Cardiovasc Res 54: 576-583, 2002.
20. Simons M, Ware JA. Therapeutic angiogenesis in cardiovascular disease. Nat Rev Drug Discov 2: 863-871, 2003.
21. Sinusas AJ. Imaging of angiogenesis. J Nucl Cardiol 11: 617-633, 2004.
22. Sinusas AJ. The potential for myocardial imaging with hypoxia markers. Semin Nucl Med 29: 330-338, 1999.
23. 99mTc-labeled nitroimidazole (BMS-181321), after regional ischemia and reperfusion. Circulation 92: 1246-1253, 1995.
24. Stupack DG, Puente XS, Boutsaboualoy S, Storgard CM, Cheresh DA. Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins. J Cell Biol 155: 459-470, 2001.
25. Takagi J, Petre BM, Walz T, Springer TA. Global conformational rearrangements in integrin extracellular domains in outside-in and insideout signaling. Cell 110: 599-511, 2002.
26. Walton HL, Corjay MH, Mohamed SN, Mousa SA, Santomenna LD, Reilly TM. Hypoxia induces differential expression of the integrin receptors alpha(vbeta3) and alpha(vbeta5) in cultured human endothelial cells. J Cell Biochem 78: 674-680, 2000.
27. Woodside DG, Liu S, Ginsberg MH. Integrin activation. Thromb Haemost 86: 316-323, 2001.